.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Novartis
Express Scripts
Teva
UBS
Johnson and Johnson
Argus Health
US Department of Justice
Federal Trade Commission
Medtronic

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203314

« Back to Dashboard
NDA 203314 describes TRESIBA, which is a drug marketed by Novo Nordisk Inc and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug. Additional details are available on the TRESIBA profile page.

The generic ingredient in TRESIBA is insulin degludec. There are thirty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the insulin degludec profile page.

Summary for NDA: 203314

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1

Pharmacology for NDA: 203314

Ingredient-typeInsulin

Suppliers and Packaging for NDA: 203314

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRESIBA
insulin degludec
SOLUTION;SUBCUTANEOUS 203314 NDA Novo Nordisk 0169-2550 0169-2550-13 3 SYRINGE, PLASTIC in 1 CARTON (0169-2550-13) > 3 mL in 1 SYRINGE, PLASTIC
TRESIBA
insulin degludec
SOLUTION;SUBCUTANEOUS 203314 NDA Novo Nordisk 0169-2550 0169-2550-97 1 SYRINGE, PLASTIC in 1 CARTON (0169-2550-97) > 3 mL in 1 SYRINGE, PLASTIC

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength300 UNITS/3ML (100 UNITS/ML)
Approval Date:Sep 25, 2015TE:RLD:Yes
Patent:6,899,699Patent Expiration:Jan 2, 2022Product Flag?YSubstance Flag?Delist Request?
Patent:7,615,532Patent Expiration:May 25, 2025Product Flag?YSubstance Flag?YDelist Request?
Patent:8,672,898Patent Expiration:Jan 2, 2022Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
US Army
McKinsey
Merck
Harvard Business School
Novartis
AstraZeneca
Dow
McKesson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot